Payment overview · 2025
General Payments
$180.44
7 reported records · 7 companies
Healthcare provider profile · identity verified
Cory M Ryan, MD
Allopathic & Osteopathic Physicians|Family Medicine · MONTICELLO, KY · NPI 1467443879
Verified facts
What the public records show
CMS Open Payments records show Cory M Ryan, MD received $180.44 in general payments during 2025 across 7 reported records.
Indivior Inc. accounted for 44.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Vraylar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Indivior Inc. | Unresolved — no canonical attribution shown | $80.06 | 44.4% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $21.71 | 12.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.61 | 12.0% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.39 | 8.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.17 | 7.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.78 | 7.6% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $13.72 | 7.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $180.44 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $80.06 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 550 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 372 | 61 |
| Oxycodone Hcl | Oxycodone Hcl | 342 | 79 |
| Lisinopril | Lisinopril | 328 | 82 |
| Atorvastatin Calcium | Atorvastatin Calcium | 324 | 77 |
| Gabapentin | Gabapentin | 323 | 70 |
| Omeprazole | Omeprazole | 312 | 63 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 277 | 46 |
| Metformin Hcl | Metformin Hcl | 276 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 67 |
| Furosemide | Furosemide | 238 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 222 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 37 |
| Carvedilol | Carvedilol | 178 | 32 |
| Prednisone | Prednisone | 167 | 101 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 29 |
| Potassium Chloride | Potassium Chloride | 157 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 31 |
| Montelukast Sodium | Montelukast Sodium | 149 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 33 |
| Ibuprofen | Ibuprofen | 148 | 43 |
| Januvia | Sitagliptin Phosphate | 147 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 143 | 22 |
| Simvastatin | Simvastatin | 142 | 24 |
| Clonazepam | Clonazepam | 134 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 24 |
| Trazodone Hcl | Trazodone Hcl | 132 | 32 |
| Famotidine | Famotidine | 126 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 124 | 20 |
| Alprazolam | Alprazolam | 123 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 123 | 20 |
| Meloxicam | Meloxicam | 122 | 28 |
| Tramadol Hcl | Tramadol Hcl | 114 | 29 |
| Losartan Potassium | Losartan Potassium | 113 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 40 |
| Celecoxib | Celecoxib | 105 | 27 |
| Promethazine Hcl | Promethazine Hcl | 104 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 22 |
| Eliquis | Apixaban | 94 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 28 |
| Pregabalin | Pregabalin | 91 | 17 |
| Glipizide | Glipizide | 89 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 88 | 21 |
| Ozempic | Semaglutide | 87 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 85 | 12 |
| Trulicity | Dulaglutide | 83 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 63 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 17 |
| Lorazepam | Lorazepam | 80 | 31 |
| Atenolol | Atenolol | 77 | 16 |
| Azithromycin | Azithromycin | 74 | 67 |
| Bumetanide | Bumetanide | 72 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 72 | 22 |
| Cefdinir | Cefdinir | 70 | 52 |
| Fentanyl | Fentanyl | 69 | 14 |
| Farxiga | Dapagliflozin Propanediol | 66 | 17 |
| Levofloxacin | Levofloxacin | 66 | 49 |
| Metformin Hcl Er | Metformin Hcl | 66 | 11 |
| Sertraline Hcl | Sertraline Hcl | 66 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | suppressed |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 54 | suppressed |
| Allopurinol | Allopurinol | 53 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 53 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 13 |
| Morphine Sulfate | Morphine Sulfate | 53 | 23 |
| Testosterone Cypionate | Testosterone Cypionate | 52 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 25 |
| Methocarbamol | Methocarbamol | 51 | 18 |
| Buspirone Hcl | Buspirone Hcl | 50 | 12 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 47 | 39 |
| Ezetimibe | Ezetimibe | 47 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Naproxen | Naproxen | 46 | suppressed |
| Sucralfate | Sucralfate | 46 | 17 |
| Dexlansoprazole Dr | Dexlansoprazole | 45 | suppressed |
| Jardiance | Empagliflozin | 44 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 11 |
| Glimepiride | Glimepiride | 41 | suppressed |
| Lansoprazole | Lansoprazole | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 38 | 25 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 14 |
| Risperidone | Risperidone | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Amoxicillin | Amoxicillin | 31 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 16 |
| Fluconazole | Fluconazole | 30 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | 12 |
| Temazepam | Temazepam | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 25 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Vraylar | Cariprazine Hcl | 23 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Nystatin | Nystatin | 21 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 13 |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 13 |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Zafemy | Norelgestromin/Ethin.Estradiol | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Tetracycline Hcl | Tetracycline Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $180.44 · 7 records | Indivior Inc. | BRIXADI, FANAPT, QULIPTA, REXULTI, SUBLOCADE, UBRELVY, VIVITROL, VYKAT XR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error